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Potentiation of ischemic renal injury by amino acid infusion. The
purpose of this study was to determine whether amino acid hyperali-
mentation sensitizes the kidney to ischemic renal injury. Sprague-
Dawley rats were infused with a control infusate or control infusate plus
15 essential and nonessential amino acids (FreAmine III, 2 mg of amino
acids/kglmin). After I hr, bilateral renal ischemia was induced (15 mm
pedicle cross clamp). GFR, urine flow, and renal blood flow (RBF)
were measured before and for 0 to 2 hr postischemia. None of these
parameters were statistically different between the two groups of rats
prior to renal ischemia. However, the decrease in GFR following renal
ischemia was twice as great in the amino acid versus the nonamino acid
treatment group (l 73 4% vs. 36 4%, respectively; P < 0.001).
The postischemia urine flow rate was also significantly less (P < 0.01)
with amino acid treatment. RBF did not differ between the two groups.
Renal histology confirmed greater tubular injury with amino acid
treatment (P < 0.001). In conclusion, infusion of therapeutic doses of
amino acids can exacerbate early functional and histologic parameters
of ischemic renal injury and thus, may sensitize the kidney to ischemic
acute renal failure.
Potentialisation de Ia lesion ischemique rénale par perfusion d'acides
aminés. Le but de cette étude a été de determiner si l'hyperalimentation
par des acides aminés sensibilise le rein a une lesion ischemique rénale.
Des rats Sprague-Dawley ont Cté perfusés avec une perfusion contrôle,
ou une perfusion contrôle plus 15 acides aminds essentiels et non
essentiels (FreAmine III, 2 mg d'acides amines/kg/min). Après I hr, une
ischémie rénale bilatérale a été induite (clampage de 15 mm du
pedicule). Le debit de GFR, le debit urinaire, et le debit sanguin renal
(RBF) ont été mesurés avant et o a 2 hr aprés ischémie. Aucun de ces
parametres n'était statistiquement different entre les deux groupes de
rats avant l'ischCmie rénale. Cependant La diminution de GFR après
l'ischémie rCnale était deux fois plus grande dans le groupe traité par les
acides aminés par rapport au groupe non traité ( 73 4% contre 36
4%, respectivement; P < 0,001). Le debit urinaire post-ischémique
était egalement significativement moindre (P < 0,01) avec le traitement
par les acides aminés. RBF n'était pas different entre les deux groupes.
L'histologie rénale a confirmé Ia plus grande atteinte tubulaire avec le
traitement par acides aminés (P < 0,001). Dans conclusion, La perfusion
de doses therapeutiques d'acides aminés peut exacerber les paramètres
précoces fonctionnels et histologiques de lesion ischémique rénale, et
ainsi peut sensibiliser le rein a l'insuffisance rénale aigué ischemique.
Hyperalimentation with amino acid solutions is widely used
in an attempt to improve the nutritional status of critically ill
patients. Because such individuals frequently develop hypoten-
sion (for example, due to sepsis, blood loss, anesthesia, and so
forth), ischemic acute renal failure (ARF) often results. Howev-
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er, the influence of amino acid administration on the renal
response to ischemia has not been defined. A growing body of
information indicates that amino acids have a nephrotoxic
potential. For example, large doses of serine [1, 2], ethionine
[3], L arginine, lysine, glutamic acid, aspartic acid, glycine, and
alanine [4] can induce experimental ARF. If large dosages of
amino acids can induce overt nephrotoxicity, it seems possible
that therapeutic dosages might cause occult renal injury which
might then sensitize the kidney to a superimposed ischemic
event. The purpose of this study was to test this hypothesis.
Methods
Female Sprague-Dawley rats (N = 57; 160 to 235 g; Charles
River Breeding Labs, Wilmington, Massachusetts) housed un-
der standard laboratory conditions were anesthetized with a
thiobarbiturate (mactin, 150 mg/kg; Byk, West Germany) and
were then subjected to tracheostomy (PE 240), to double
catheterization of the left jugular vein, (PE-50), and to a 1-cm
midline suprapubic laparotomy to expose the urinary bladder.
One venous line was used to infuse at a rate of 2.4 mI/hr either:
(1) control infusate (half normal saline; 10,000 cpm/ml sodium
iothalamate 125j; 125 zg/ml furosemide) or (2) the same infusate
to which was added 9.4 mg/ml of mixed amino acids. The
source of the amino acids was FreAmine III, (McGaw, Irvine,
California) which is a clinically employed mixture of 15 essen-
tial and nonessential amino acids. The amino acid delivery rate
was approximately 2.0 mg/kg/mm, a dosage which is used in a
pediatric patient population (McGaw, product information).
Furosemide (Hoechst, Somerville, New Jersey) was added to
both the control and amino acid infusates to (1) induce a
sufficient rate of diuresis to permit GFR determinations (C10
thalamate 1251) [5] every 20 mm throughout the experiments and
(2) to prevent the volume-expanded state that would have
resulted from a half normal saline infusion. With the dosage of
furosemide used urine flow rate approximated the intravenous
infusion rate. If any fluid deficit was noted (intake versus every
20-mm urine output), the deficit was replaced immediately with
half normal saline through the second intravenous catheter.
Urine was collected from the urinary bladder every 20 mm by
bathing the exposed bladder serosa with 20 d of bethanechol
(1:10 dilution) (Urecholine; Merck, Sharpe, Dohme, West
Point, Pennsylvania) to stimulate bladder contraction. This was
followed by very gentle bladder compression exerted through
temporarily repositioned abdominal musculature. The com-
pleteness of bladder emptying by this technique was confirmed
after each collection by direct visual inspection. A simultaneous
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75 l tail vein blood sample was obtained every 20 mm at the
time of bladder emptying. Urine and serum samples were
counted in a gamma counter for 1 mm and 5 mm, respectively,
and GFR was determined for each 20-mm collection period by
calculating the clearance of iothalamate 1251 The reliability of
this technique for determining GFR has been ascertained previ-
ously (for example, [4—6]).
Renal ischemia protocol. Rats were infused with either the
control infusate (N = 12) or with the amino acid infusate (N =
12). A 0.5 ml prime (over 5 mm) was given at the start of each
experiment, followed by the constant infusion rate of 2.4 mI/hr.
The first two 20-mm urine samples were discarded (equilibra-
tion period). The next two 20-mm collection periods were
designated the pre-ischemia period, and the mean GFR and
urine flow rate for this period were determined for each rat.
Following completion of the pre-ischemia period, the midline
suprapubic incision was extended to the xiphoid, the kidneys
were exposed, the perinephric fat was dissected away, and both
renal vascular pedicles were clamped x 15 mm. Upon comple-
tion of this ischemia period, the vascular clamps were removed,
uniform re-perfusion as assessed by visual inspection was
confirmed, and then the abdominal incision was closed (except
over the bladder). GFR was again determined every 20 mm for
an additional 2 hr. The last 40 mm of each experiment was
designated the final postischemia period, and the mean GFR
and urine flow rate for this period were determined. Upon
completion of this period, six rats in the control infusion group
and six rats in the amino acid infusion group were sacrificed by
phlebotomy and Na, K, Cl, C02, and phosphate
concentrations were determined (ACA, Dupont, Wilmington,
Delaware).
Renal histology. The remaining nonphlebotomized rats in the
control infusion group (N = 6) and in the amino acid infusion
group (N 6) had their left kidneys fixed by in vivo retrograde
perfusion for subsequent histologic evaluation. The abdominal
aorta was catheterized just above the origin of the iliac arteries
with a 14-gauge Teflon catheter, the left renal vein was cut, and
then retrograde aortic perfusion was immediately begun with
1.25% glutaraldehyde in a 0.1 M Na cacodylate buffer (pH 7.4)
at a pressure of 140 mm Hg. The abdominal aorta was then
immediately ligated just above the origin of the left renal artery.
After 5 mm of perfusion the left kidney was removed and a
transverse kidney section (cortex to papilla) was immersed in
10% buffered formalin. The tissue samples were imbedded in
paraffin and 4-j sections were stained with hematoxylin and
eosin. The slides were coded and then evaluated in a blinded
fashion. The severity of renal injury was graded semiquantita-
tively on a scale of 0 to 10 when 0 equaled normal histology and
10 equaled total tubular necrosis. Differences in histology
grades between the two groups of rats were tested statistically
by the Wilcoxon rank sum test.
Renal ischemia experiments: hemodynamic monitoring. The
following experiments were performed to determine whether
there were major hemodynamic changes induced by the amino
acid infusion during the course of the ischemia experiments:
Ten rats were surgically prepared as previously described. In
addition, a PE 50 catheter was placed into the left carotid artery
which was attached to a P 23 Gould Statham pressure transduc-
er for monitoring mean arterial blood pressure (Sensotec
#D500, Columbus, Ohio). Then, the midline abdominal incision
was extended to the xiphoid to expose the renal pedicles, a 1.5
mm flow probe (EP 101.5, Carolina Medical Instruments, King,
North Carolina) was positioned around the left renal artery, and
the probe was connected to an electromagnetic flow meter
(Model 501, Carolina Medical Instruments). The flow probe had
been calibrated previously by ex vivo carotid artery perfusion
with whole blood. The abdominal incision was closed (except
over the bladder) and 1 ml of half normal saline was infused (x 5
mm) to replete possible fluid losses incurred during placement
of the flow probe. Fifteen minutes were allowed for renal blood
flow (RBF) to stabilize. Then the rats received either the
control infusate (N = 5) or the amino acid infusate (N = 5) as
previously described (0.5 ml prime, then 2.4 ml/hr). The remain-
der of the experiments were performed exactly as noted previ-
ously. The left renal pedicle clamp was placed just distal to the
flow probe. Two hours postischemia the rats were sacrificed
with an overdose of mactin.
Renal ischemia protocol: acetateiphosphatelbisulfite and
glucose infusion. The addition of FreAmine to the half normal
saline control infusate resulted in concentrations of acetate,
phosphate, and bisulfite of 8.9 mEq/liter, 2.4 mg/dl, and 11
mg/dl, respectively. To ascertain whether these components of
the FreAmine solution alter the renal response to ischemia,
independent of amino acids, sodium acetate, phosphate, and
bisulfite were added to the control infusate to create the above
concentrations and the 15-mm renal ischemia protocol was
performed on three rats. The effect of this infusate was assessed
by comparing pre-ischemic and postischemic renal function
with values previously established for the nonamino acid-
infused ischemic rats.
The addition of the amino acids to the control infusate
resulted in an 85 mOsm/liter increase in the osmolality of the
solution. To ascertain that this increased osmolality had no
effect on the renal response to injury, the osmolality of the
above acetate/phosphate/bisulfite solution was increased 85
mOsm/liter by the addition of glucose. The immediately above
described experiment was performed on three additional rats.
Renal ischemia experiments: discontinued amino acid infu-
sion. To ascertain whether the adverse effect of amino acid
infusion on renal function postischemia requires continued
amino acid administration, five rats were subjected to the renal
ischemia protocol, but the control infusate was substituted for
the amino acid infusate during the period of vascular clamping.
It was continued for the remainder of the experiments. The
protocol was otherwise identical to that noted previously.
Renal ischemia experiments: mannitol diuresis, 25-mm ische-
mic period. To exclude the possibility that the amino acid-
induced decrement in GFR postrenal ischemia was furosemide-
dependent or that this effect is observed only with 15 mm of
renal ischemia, the following experiments were performed:
Eight rats were surgically prepared as previously described and
infused (2.4 ml/hr) with either a control infusate (one-half
normal saline/10% mannitol/iothalamate) (N four rats) or this
same infusate to which the amino acids were added (N = four
rats). The previous ischemia protocol was then performed
except that the length of ischemia was increased to 25 mm.
Renal function pre- and postischemia in the amino acid and
nonamino acid treatment groups were compared.
Amino acid infusion without renal ischemia. To determine
whether 3 hr of amino acid infusion has an effect on GFR
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Table 1. Renal function pre- and post-iS mm of renal ischemia with and without amino acid treatment'
Pre-ischemid' Postischemia'
Urine Urine
GFR flow RBF GFR % GFR' flow RBF
Amino acids (Continuous infusion) 0.79 0.03 16 1 4.2 0.2 0.21 0.03 73 4% 12 1 4.1 0.3
No amino acids 0.73 0.03 18 1 4.5 0.3 0.47 0.03 36 4% 17 1 4.0 0.4
P NS NS NS <0.001 <0.001 <0.01 NS
Abbreviations: GFR, Ciothalamate ml/min/lOO g body weight; urine flow, pi/min/100 g body weight; (determined in 17 rats in each group, five of
which were subjected to the hemodynamic monitoring); RBF, single kidney renal blood flow (determined in five rats in each group).
a Values given are means SEM.
b The pre-ischemia period is the 40-mm prior to vascular clamping.
The postischemia period is the last 40 mm of the experiments.
The percent decrease in GFR was derived by comparing the pre- and postischemia period GFRs.
Table 2. Terminal serum electrolytes: Amino acid and nonamino acid-infused ratsa
Na K C1 HC03 Ca Pi
Amino acids (Continuous infusion) 135 3 5.2 0.2 93 2 27 1 5.2 0.1 11.0 0.3
No amino acids 135 2 4.8 0.1 95 1 24 1 4.9 0.1 10.6 0.2
a Sera were obtained upon completion of the 15-mm ischemia experiments (N = 6 for each group). Values are expressed in mEq/liter (mean
sF54) except for Pi (inorganic phosphate) which is in mg/dI. There were no significant differences (P < 0.05) noted between the two groups of rats.
independent of superimposed renal ischemia, the following
experimental protocol was performed. Four rats were surgically
prepared as described previously and then they were infused
with the control infusate (2.4 ml/hr). After completion of the
equilibration period and a 40-mm control infusion period, the
amino acid infusate was substituted for the control infusate and
administered (2.4 ml/hr) for 3 hr. Renal function (GFR, urine
flow rate) for the 40-mm control infusion period and for the last
40 mm of the amino acid infusion period were compared by
paired t test. At the end of these experiments, renal histological
sections were prepared as previously described.
Calculations and statistics. GFR and urine flow rates were
factored by body weight and are expressed as ml/min/100 g
SEM and p1/min/ 100 g SEM, respectively. GFR and urine flow
rates designated as pre-ischemia and final postischemia values
represent mean values for the 40 mm prior to renal clamping
and for the last 40 mm of the experiments. The percent loss of
GFR induced by ischemia was derived by comparing pre-
ischemia and final postischemia GFRs. GFR, percent loss of
GFR, and urine flow rates for amino acid and nonamino acid-
treated rats were compared by unpaired t test. Significance was
judged by a P of < 0.05.
Results
Renal ischemia protocol. GFR and urine flow rates for the
amino acid and nonamino acid-infused rats are presented in
Table 1. There were no significant differences in these parame-
ters between the two groups of rats prior to renal ischemia.
However, final postischemia GFRs and urine flow rates were
both significantly lower in the amino acid treatment group. The
amino acid infused rats lost twice as much of their baseline GFR
in response to ischemia as did the nonamino acid-treated rats
(73% versus 36%, P < 0.001). The sequential changes in GFR
during these experiments are presented in Figure 1. None of the
terminal serum electrolyte concentrations for the two groups of
rats were significantly different (Table 2).
Renal ischemia protocol: hemodynamic monitoring. Mean
arterial blood pressures for the amino acid and nonamino acid
infused rats were 99 2 and 98 3 mm Hg, respectively. Single
kidney RBF during the experiments are presented in Figure 1
and in Table 1. RBF showed no significant change over basal
values with the initiation of either the control or the amino acid
infusates. No significant differences in RBF were noted at any
time during the experiments between the two groups of rats.
Pre-ischemia GFRs for these rats were: amino acid group, 0.81
0.09; nonamino acid group, 0.80 0.09 (NS). Final postis-
chemia GFRs were: amino acid group 0.13 0.03 (.j, 84 4%);
nonamino acid group, 0.39 0.05 ( 51 6%) (P < 0.001).
Renal ischemia protocol: acetate, phosphate, bisulfite, and
glucose infusion. The acetate, phosphate, and bisulfite infusion
(nonamino acid constituents of FreAmine) had no significant
effect on the ischemia experiments, Pre- and final postischemia
GFRs were 0.73 0.02 and 0.49 0.03, respectively (GFR
. 33 4%). Pre-ischemia and final postischemia urine flow
rates were 16 1 and 17 2, respectively. None of these
values were significantly different from those observed in the
previous nonamino acid-treated ischemia rats. Addition of
glucose to this infusate (to raise the osmolality by 85 mOsm/
liter) had no significant effect on renal function pre- or postis-
chemia: GFR, pre 0.66 0.01, post 0.38 0.01; ( 42 1%);
urine flow, pre 25 2, post 15 1.
Renal ischemia protocol: discontinued amino acid infusion.
The amino acid infusion confined to the pre-ischemia period
also exacerbated the ischemia-induced decline in GFR. This
group of rats had a pre-ischemia GFR of 0.80 0.02. Final
postischemia GFR was 0.29 0.06 ( 64 6%) (P < 0.02
versus nonamino acid-infused rats). This percent loss in GFR
was not significantly different from that which was observed in
the ischemic rats that had received the constant amino acid




Fig. 1. RBF (top) and GFR (bottom) pre- and post-15 mm of renal
ischemia. Broken lines represent rats treated with continuous amino
acid infusion (N = 17). Solid lines represent nonamino acid-treated rats(N = 17). Each collection period was 20 mm. RBF (determined in five
rats in each group) was not statistically different between the two
groups at any time during the experiments. GFR was not statistically
different between the two groups until the second postischemia period
(P < 0.01). It then remained significantly lower (P < 0.001) for the
remainder of the experiments. Values given are means SEM.
infusion. Pre-ischemia and postischemia urine flow rates were
16 3 and 16 4, respectively.
Renal ischemia protocol: 25-mm ischemialmannitol diuresis.
Amino acid infusion also exacerbated ischemic renal injury (25-
mm cross clamping) in rats undergoing a mannitol diuresis. Pre-
ischemia GFR for these amino acid and nonamino acid-infused
rats were 0.71 0.07 and 0.77 0.02, respectively (NS). Final
postischemia GFRs were: amino acid infused, 0.15 0.02 ( 79
5%); nonamino acid infused, 0.39 0.03 ( 49 1%) (P <
0.05). Urine flow rates pre- and postischemia were: amino acid
infused rats, 20 2 and 29 2; nonamino acid infused rats, 19
1 and 28 5, respectively (NS).
Amino acid infusion without renal ischemia. GFR was not
significantly affected by 3 hr of amino acid infusion in the
absence of renal ischemia. The pre-amino acid infusion period
GFR was 0.77 0.05; at the end of 3 hr of amino acid infusion
GFR was 0.72 0.03 (NS, paired t test).
Renal histology. A spectrum of histopathologic changes was
encountered in all postischemic kidneys from amino acid-
treated rats (Fig. 2A). These changes included the formation of
free floating vesicular structures ("blebs") in proximal tubules,
impaction of such blebs in proximal straight tubules and Hen-
le's loop, uncommon foci of epithelial necrosis in proximal
tubules and thick segments of Henle's loops, and formation of
hyaline or granular casts in distal nephron segments. Blebs in
proximal tubular lumina were shown to be derived from injured,
disintegrated plasma membrane. In three of six kidneys there
also was prominent dilatation of proximal tubules (Fig. 2A).
Glomeruli and blood vessels revealed no pathology. In the
control group (without amino acids), the lesions were either not
present or were extremely mild (Fig. 2B). The histologic
difference between the two groups was also attested by the
ability of the blinded observer to accurately allocate each
kidney correctly to its respective group (Fig. 3). By Wilcoxon
test, the amino acid and nonamino acid-treated groups had
statistically different histologic scores (P < 0.001). Rats subject-
ed to amino acid infusion without superimposed renal ischemia
had normal (grade 0) renal histology.
Discussion
In a previous study [4] we demonstrated that amino acids
when administered in dosages comparable to those used in a
human lysine infusion test [7, 8] can induce ARF in the normal
rat. Other investigators had previously suggested that a limited
number of amino acids with specific molecular characteristics
have nephrotoxic potentials [1—3]. However, our study [4]
indicated that amino acid nephrotoxicity is not highly com-
pound specific since acute renal injury could be induced by
each of six amino acids tested regardless of the nature of their R
groups. The additional finding that glycine (which has no R
group) could cause acute renal injury suggests that amino acid
nephrotoxicity may arise, in part, from the constant portion of
amino acid molecules.
The dosages of amino acids used in each of these previous
studies [1—4] far exceed the quantities which are given to
patients for the purpose of hyperalimentation. However, if
amino acids have an overt nephrotoxic effect at high infusion
rates then it seems possible that therapeutic doses might induce
occult renal injury and, thus, render the kidney more suscepti-
ble to a superimposed insult. That a nephrotoxic agent can
predispose to ischemic renal injury has been demonstrated
recently with gentamicin [9]. The present results suggest that
amino acids have a similar effect. FreAmine-infused rats lost
73% of their baseline GFR in response to 15 mm of renal
ischemia while control rats lost only 36%. FreAmine infusion,























Fig. 2. Light micrographs of kidneys from
amino acid treated (A) and control (B) rats
subjected to 15 mm of ischemia. (x304)
A Proximal tubules in inner cortex-outer stripe
of outer medulla from amino acid-treated rat
with differently sized blebs in tubular lumina
(arrowheads). In other areas, the tubules are
impacted with blebs, amorphous material, and
debris (asterisks). Most tubules are
abnormally dilated, with thin epithelium.
B Proximal tubules in inner cortex-outer stripe
of outer medulla from the control rat. Despite
ischemia, the tubules maintain their integrity
and appear almost normal.
mia-induced decline in GFR. This further supports the notion
that FreAmine can sensitize the kidney to ischemic injury.
The mechanism by which FreAmine exerts this adverse effect
remains to be defined. However, the available data do permit a
number of conclusions to be drawn. First, FreAmine's influ-
ence on ischemic renal injury must be ascribed to the amino
acid components of the FreAmine solution since the nonamino
acid constituents (acetate, phosphate, and bisulfite) had no
demonstrable effect on postischemic renal function. Second,
the observed exacerbation of renal injury with FreAmine can-
not be explained by the additive effect of amino acid nephrotox-
icity to ischemic renal injury since there is no evidence that the
FreAmine exerted an independent effect on renal function.
GFR and urine flow rates were comparable in FreAmine and
non-FreAmine-treated rats prior to renal ischemia. Further-
more, renal function and histology remained normal in rats
subjected to 3 hr of FreAmine infusion in the absence of
superimposed ischemia. Third, the greater postischemic decline
in GFR in the FreAmine treatment group cannot be readily
ascribed to alterations in RBF. No significant differences in
RBF were noted between the two groups of rats at any time
during the experiments. Furthermore, RBF by the end of the
experiments approximated values found prior to renal ischemia.
Thus, one would need to postulate that FreAmine caused either
a large intrarenal shunting of blood away from functional
nephrons or that it induced a combination of increased afferent
and decreased efferent arteriolar resistance to account for the
observations of normal RBF with a substantially reduced GFR.
Neither of these two possibilities have well established clinical
or experimental precedents. Fourth, the increased proximal
tubular injury in the FreAmine treatment group indicates that
the greater postischemic reductions in GFR were not merely
functional (that is, RBF, Kf) in nature. FreAmine caused
increased brushborder blebbing and proximal tubular cell ne-
crosis, results which led to impaction of multiple tubular
segments with cellular debris. Concomitant tubular dilatation
implies that tubular obstruction resulted which could have
caused, or contributed to, the greater postischemic declines in
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Fig. 3. Semiquantitative histologic grading for each histologic section.
Numbers represent the range: 0, normal histology; 10, total renal
parenchymal necrosis. The two groups were statistically different (P <
0.001, Wilcoxon test).
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GFR. These histologic abnormalities, characteristic of ischemic
renal injury [10, 11], were virtually confined to the FreAmine-
treated rats. Thus, both histologic and functional data support
the notion that FreAmine can potentiate ischemic renal injury.
The clinical significance of these results clearly need to be
established. Hyperalimentation is a widely used therapeutic
modality with proven nutritional benefits. Thus, the present
data as well as previous suggestions that amino acids may
potentiate aminoglycoside nephrotoxicity [12, 13] need to be
intrepreted with caution. Conversely, other studies which sug-
gest that amino acid hyperalimentation may have a salutory
effect on ARF [14, 15] also need to be scrutinized, particularly
since this conclusion has not been confirmed by additional
investigations [16, 17]. Such paradoxical findings might arise if
amino acids have multiple and counterbalancing effects on the
acutely injured kidney. For example, amino acids may increase
renal phospholipid biosynthesis [18] which could enhance re-
covery from ARF. On the other hand, the intrinsic nephrotoxic-
ity of amino acids might overwhelm this beneficial effect
depending on when, for how long, in what dosage, or which
amino acids are administered. We believe that such potential
interactions represent important areas for future investigation.
